BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Margetts J, Ogle LF, Chan SL, Chan AWH, Chan KCA, Jamieson D, Willoughby CE, Mann DA, Wilson CL, Manas DM, Yeo W, Reeves HL. Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma? Br J Cancer. 2018;118:248-257. [PMID: 29123264 DOI: 10.1038/bjc.2017.386] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Malehmir M, Pfister D, Gallage S, Szydlowska M, Inverso D, Kotsiliti E, Leone V, Peiseler M, Surewaard BGJ, Rath D, Ali A, Wolf MJ, Drescher H, Healy ME, Dauch D, Kroy D, Krenkel O, Kohlhepp M, Engleitner T, Olkus A, Sijmonsma T, Volz J, Deppermann C, Stegner D, Helbling P, Nombela-arrieta C, Rafiei A, Hinterleitner M, Rall M, Baku F, Borst O, Wilson CL, Leslie J, O’connor T, Weston CJ, Adams DH, Sheriff L, Teijeiro A, Prinz M, Bogeska R, Anstee N, Bongers MN, Notohamiprodjo M, Geisler T, Withers DJ, Ware J, Mann DA, Augustin HG, Vegiopoulos A, Milsom MD, Rose AJ, Lalor PF, Llovet JM, Pinyol R, Tacke F, Rad R, Matter M, Djouder N, Kubes P, Knolle PA, Unger K, Zender L, Nieswandt B, Gawaz M, Weber A, Heikenwalder M. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med 2019;25:641-55. [DOI: 10.1038/s41591-019-0379-5] [Cited by in Crossref: 83] [Cited by in F6Publishing: 86] [Article Influence: 27.7] [Reference Citation Analysis]
2 Zhang Y, Lin S, Yang X, Wang R, Luo L. Prognostic value of pretreatment systemic immune-inflammation index in patients with gastrointestinal cancers. J Cell Physiol 2019;234:5555-63. [PMID: 30353545 DOI: 10.1002/jcp.27373] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
3 Liu Y, Meng X. Comment on 'Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?'. Br J Cancer 2018;119:779-80. [PMID: 30206367 DOI: 10.1038/s41416-018-0241-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Wang B, Huang Y, Lin T. Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2020;99:e18571. [PMID: 31895801 DOI: 10.1097/MD.0000000000018571] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
5 Ma C, Liu Q, Li C, Cheng J, Liu D, Yang Z, Yan H, Wu B, Wu Y, Zhao J. Novel Blood Indicators of Progression and Prognosis in Renal Cell Carcinoma: Red Cell Distribution Width-to-Lymphocyte Ratio and Albumin-to-Fibrinogen Ratio. J Oncol 2020;2020:2895150. [PMID: 33299415 DOI: 10.1155/2020/2895150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu LT, Liang YJ, Guo SS, Xie Y, Jia GD, Wen DX, Tang LQ, Chen QY, Mai HQ. Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: A study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA. Head Neck 2021. [PMID: 34636116 DOI: 10.1002/hed.26897] [Reference Citation Analysis]
7 Bartneck M, Wang J. Therapeutic Targeting of Neutrophil Granulocytes in Inflammatory Liver Disease. Front Immunol 2019;10:2257. [PMID: 31616430 DOI: 10.3389/fimmu.2019.02257] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
8 Kaltenmeier CT, Yazdani H, van der Windt D, Molinari M, Geller D, Tsung A, Tohme S. Neutrophil extracellular traps as a novel biomarker to predict recurrence-free and overall survival in patients with primary hepatic malignancies. HPB (Oxford) 2021;23:309-20. [PMID: 32811764 DOI: 10.1016/j.hpb.2020.06.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Xu Y, He X, Deng J, Xiong L, Li Y, Zhang X, Chen W, Liu X, Xu X. Comprehensive Analysis of the Immune Infiltrates and PD-L1 of m6A RNA Methylation Regulators in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:681745. [PMID: 34277622 DOI: 10.3389/fcell.2021.681745] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Patten DA, Wilkinson AL, O'Rourke JM, Shetty S. Prognostic Value and Potential Immunoregulatory Role of SCARF1 in Hepatocellular Carcinoma. Front Oncol 2020;10:565950. [PMID: 34354939 DOI: 10.3389/fonc.2020.565950] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Hong YM, Yoon KT, Hwang TH, Cho M. Pretreatment peripheral neutrophils, lymphocytes and monocytes predict long-term survival in hepatocellular carcinoma. BMC Cancer 2020;20:937. [PMID: 32993594 DOI: 10.1186/s12885-020-07105-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lo CH, Lee HL, Hsiang CW, Chiou JF, Lee MS, Chen SW, Shen PC, Lin CS, Chang WC, Yang JF, Dai YH, Chen CY, Chia-Hsien Cheng J, Huang WY. Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival and Liver Toxicity in Patients With Hepatocellular Carcinoma Treated With Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys 2021;109:474-84. [PMID: 32898609 DOI: 10.1016/j.ijrobp.2020.09.001] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Kim CG, Kim C, Yoon SE, Kim KH, Choi SJ, Kang B, Kim HR, Park SH, Shin EC, Kim YY, Kim DJ, Chung HC, Chon HJ, Choi HJ, Lim HY. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. J Hepatol. 2021;74:350-359. [PMID: 32810553 DOI: 10.1016/j.jhep.2020.08.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
14 Chan SL, Wong LL, Chan KA, Chow C, Tong JH, Yip TC, Wong GL, Chong CC, Liu PH, Chu CM, Wong VW, To KF, Reeves HL, Chan AW. Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. Liver Cancer 2020;9:167-81. [PMID: 32399431 DOI: 10.1159/000504252] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
15 Wu W, Wang Q, Han D, Li J, Nie Y, Guo D, Yang L, Tao K, Zhang X, Dou K. Prognostic value of preoperative inflammatory markers in patients with hepatocellular carcinoma who underwent curative resection. Cancer Cell Int 2021;21:500. [PMID: 34535132 DOI: 10.1186/s12935-021-02204-3] [Reference Citation Analysis]
16 Concetti J, Wilson CL. NFKB1 and Cancer: Friend or Foe? Cells 2018;7:E133. [PMID: 30205516 DOI: 10.3390/cells7090133] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
17 Chan SL, McNally RJQ, Reeves HL. Reply to 'Comment on 'Circulating Neutrophils in patients with hepatocellular carcinoma". Br J Cancer 2018;119:781-2. [PMID: 30206368 DOI: 10.1038/s41416-018-0250-3] [Reference Citation Analysis]
18 Ramadori P, Klag T, Malek NP, Heikenwalder M. Platelets in chronic liver disease, from bench to bedside. JHEP Rep. 2019;1:448-459. [PMID: 32039397 DOI: 10.1016/j.jhepr.2019.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Diao P, Wu Y, Ge H, Li J, Zhang W, Huang R, Wang Y, Cheng J. Preoperative circulating platelet, neutrophil, and lymphocyte counts predict survival in oral cancer. Oral Dis 2019;25:1057-66. [DOI: 10.1111/odi.13049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
20 Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, Clark W, Gilroy K, Hedley A, Nixon C, Luli S, Laszczewska M, Pinyol R, Esteban-Fabró R, Willoughby CE, Haber PK, Andreu-Oller C, Rahbari M, Fan C, Pfister D, Raman S, Wilson N, Müller M, Collins A, Geh D, Fuller A, McDonald D, Hulme G, Filby A, Cortes-Lavaud X, Mohamed NE, Ford CA, Raffo Iraolagoitia XL, McFarlane AJ, McCain MV, Ridgway RA, Roberts EW, Barry ST, Graham GJ, Heikenwälder M, Reeves HL, Llovet JM, Carlin LM, Bird TG, Sansom OJ, Mann DA. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut 2022:gutjnl-2021-326259. [PMID: 35477863 DOI: 10.1136/gutjnl-2021-326259] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wang L, Jin YX, Ji YZ, Mu Y, Zhang SC, Pan SY. Development and validation of a prediction model for microvascular invasion in hepatocellular carcinoma. World J Gastroenterol 2020; 26(14): 1647-1659 [PMID: 32327913 DOI: 10.3748/wjg.v26.i14.1647] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
22 Golonka RM, Vijay-Kumar M. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome. Adv Cancer Res 2021;149:171-255. [PMID: 33579424 DOI: 10.1016/bs.acr.2020.10.004] [Reference Citation Analysis]
23 Geh D, Leslie J, Rumney R, Reeves HL, Bird TG, Mann DA. Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35022608 DOI: 10.1038/s41575-021-00568-5] [Reference Citation Analysis]
24 Mroweh M, Decaens T, Marche PN, Macek Jilkova Z, Clément F. Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5250. [PMID: 32722054 DOI: 10.3390/ijms21155250] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Fan Y, Li S, Ding X, Yue J, Jiang J, Zhao H, Hao R, Qiu W, Liu K, Li Y, Wang S, Zheng L, Ye B, Meng K, Xu B. First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers. BMC Cancer 2019;19:279. [PMID: 30922248 DOI: 10.1186/s12885-019-5471-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
26 Zheng Y, Li Y, Feng J, Li J, Ji J, Wu L, Yu Q, Dai W, Wu J, Zhou Y, Guo C. Cellular based immunotherapy for primary liver cancer. J Exp Clin Cancer Res 2021;40:250. [PMID: 34372912 DOI: 10.1186/s13046-021-02030-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 García-Vilas JA, Medina MÁ. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications. World J Gastroenterol 2018; 24(33): 3695-3708 [PMID: 30197476 DOI: 10.3748/wjg.v24.i33.3695] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
28 Ustyanovska Avtenyuk N, Visser N, Bremer E, Wiersma VR. The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer. Int J Mol Sci 2020;21:E7820. [PMID: 33105656 DOI: 10.3390/ijms21217820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Carranza-Trejo AM, Vetvicka V, Vistejnova L, Kralickova M, Montufar EB. Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2021;15:783-96. [PMID: 33557653 DOI: 10.1080/17474124.2021.1887730] [Reference Citation Analysis]
30 Wu Y, Fan W, Xue M, Zhong B, Zhang S, Wang Y, Yao W, Zhao Y, Li J. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Oncologist 2019;24:e1489-95. [PMID: 31249138 DOI: 10.1634/theoncologist.2018-0669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Cruz JC, Watchmaker JM, Albin MM, Wang L, Wu G, Baker JC, Fritsche MR, Alexopoulos SP, Matsuoka L, Fleming JW, Su J, Borgmann AJ, Banovac F, Brown DB. Neutrophil/Lymphocyte Ratio Predicts Increased Risk of Immediate Progressive Disease following Chemoembolization of Hepatocellular Carcinoma. J Vasc Interv Radiol. 2019;30:1887-1892. [PMID: 31669086 DOI: 10.1016/j.jvir.2019.08.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
32 Cho Y, Szabo G. Two Faces of Neutrophils in Liver Disease Development and Progression. Hepatology 2021;74:503-12. [PMID: 33314193 DOI: 10.1002/hep.31680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Hu Z, Chen H, Chen S, Huang Z, Qin S, Zhong J, Qin X, Li S. The value of neutrophil to lymphocyte ratio and gamma-glutamyl transpeptidase to platelet ratio in patients with hepatocellular carcinoma. Medicine (Baltimore). 2019;98:e14749. [PMID: 30817633 DOI: 10.1097/md.0000000000014749] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
34 Wang Q, Qiao W, Liu B, Li J, Yuan C, Long J, Hu C, Zang C, Zheng J, Zhang Y. The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy. BMC Gastroenterol 2022;22:98. [PMID: 35246045 DOI: 10.1186/s12876-022-02180-6] [Reference Citation Analysis]
35 Hong YM, Yoon KT, Hwang TH, Heo J, Woo HY, Cho M. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol. 2019;31:1250-1255. [PMID: 30925530 DOI: 10.1097/meg.0000000000001405] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
36 Guo L, Ren H, Pu L, Zhu X, Liu Y, Ma X. The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study. Cancer Manag Res 2020;12:7173-88. [PMID: 33061563 DOI: 10.2147/CMAR.S257934] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Balaceanu LA. Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. World J Clin Cases 2019; 7(12): 1367-1382 [PMID: 31363465 DOI: 10.12998/wjcc.v7.i12.1367] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
38 Chen H, Zhou XH, Li JR, Zheng TH, Yao FB, Gao B, Xue TC. Neutrophils: Driving inflammation during the development of hepatocellular carcinoma. Cancer Lett 2021;522:22-31. [PMID: 34517084 DOI: 10.1016/j.canlet.2021.09.011] [Reference Citation Analysis]
39 Bannaga A, Arasaradnam RP. Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review. World J Gastroenterol 2020; 26(33): 5022-5049 [PMID: 32952347 DOI: 10.3748/wjg.v26.i33.5022] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:396. [PMID: 31500650 DOI: 10.1186/s13046-019-1396-4] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 25.3] [Reference Citation Analysis]
41 Zhao J, Huang W, Wu Y, Luo Y, Wu B, Cheng J, Chen J, Liu D, Li C. Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis. Cancer Cell Int 2020;20:15. [PMID: 31938023 DOI: 10.1186/s12935-020-1094-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]